Immune Responses to Viral Gene Therapy Vectors

Area of Science:

• Biotechnology
• Immunology
• Gene Therapy

Background:

• Viral vector gene therapy has advanced significantly, with approved drugs and numerous clinical trials for genetic and acquired diseases.
• The efficiency and long-term therapeutic potential of viral vectors make them attractive for treating previously untreatable conditions.

Purpose of the Study:

• To review immune responses to common viral vector systems (adenoviral, lentiviral, adeno-associated viral).
• To discuss mechanisms of immune activation, strategies to reduce immunogenicity, and potential solutions.
• To identify knowledge gaps and future research directions in viral vector gene therapy immunogenicity.

Main Methods:

• Review of documented immune responses in animal models and human clinical trials.
• Analysis of immune responses associated with adenoviral, lentiviral, and adeno-associated viral vectors.
• Examination of strategies aimed at reducing vector immunogenicity.

Main Results:

• Innate and adaptive immune responses to viral vectors and transgene products are significant hurdles.
• Specific immune responses vary among different viral vector types.
• Efforts to mitigate immunogenicity are crucial for successful clinical translation.

Conclusions:

• Understanding and overcoming immune responses are critical for the broader clinical application of gene therapy.
• Further research is needed to address remaining challenges in vector immunogenicity and develop effective solutions.
• Targeted strategies are required to enhance the safety and efficacy of viral vector-based gene therapies.